Sellas' vaccine extends survival in blood cancer trial Reuters
Sellas' vaccine extends survival in blood cancer trial - Reuters
In short
Clinical trial data shows that the vaccine produced by Sellas successfully prolonged the lives of patients suffering from blood cancer. Although the positive survival outcome has been confirmed, comprehensive clinical metrics have not been released. The original disclosure omitted specifics concerning the size and characteristics of the patient population. Future strategic steps regarding the clinical development of this vaccine remain currently undisclosed.
Key points
- The pharmaceutical developer achieved positive survival outcomes in its recent blood canc…: The pharmaceutical developer achieved positive survival outcomes in its recent blood cancer clinical trial.
- Detailed metrics regarding patient population characteristics and specific survival rates…: Detailed metrics regarding patient population characteristics and specific survival rates remain currently unavailable.
- The company has yet to publicly disclose its subsequent steps following these trial resul…: The company has yet to publicly disclose its subsequent steps following these trial results.